540 related articles for article (PubMed ID: 35024714)
1. Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery.
Cui L; Pereira S; Sonzini S; van Pelt S; Romanelli SM; Liang L; Ulkoski D; Krishnamurthy VR; Brannigan E; Brankin C; Desai AS
Nanoscale; 2022 Jan; 14(4):1480-1491. PubMed ID: 35024714
[TBL] [Abstract][Full Text] [Related]
2. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
3. Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing.
Sarode A; Fan Y; Byrnes AE; Hammel M; Hura GL; Fu Y; Kou P; Hu C; Hinz FI; Roberts J; Koenig SG; Nagapudi K; Hoogenraad CC; Chen T; Leung D; Yen CW
Nanoscale Adv; 2022 May; 4(9):2107-2123. PubMed ID: 36133441
[TBL] [Abstract][Full Text] [Related]
4. The role of lipid components in lipid nanoparticles for vaccines and gene therapy.
Hald Albertsen C; Kulkarni JA; Witzigmann D; Lind M; Petersson K; Simonsen JB
Adv Drug Deliv Rev; 2022 Sep; 188():114416. PubMed ID: 35787388
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
6. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery.
Maeki M; Uno S; Niwa A; Okada Y; Tokeshi M
J Control Release; 2022 Apr; 344():80-96. PubMed ID: 35183654
[TBL] [Abstract][Full Text] [Related]
7. Delivery Strategies for mRNA Vaccines.
Ramachandran S; Satapathy SR; Dutta T
Pharmaceut Med; 2022 Feb; 36(1):11-20. PubMed ID: 35094366
[TBL] [Abstract][Full Text] [Related]
8. The immunostimulatory nature of mRNA lipid nanoparticles.
Sharma P; Hoorn D; Aitha A; Breier D; Peer D
Adv Drug Deliv Rev; 2024 Feb; 205():115175. PubMed ID: 38218350
[TBL] [Abstract][Full Text] [Related]
9. High-Throughput
Hamilton AG; Swingle KL; Thatte AS; Mukalel AJ; Safford HC; Billingsley MM; El-Mayta RD; Han X; Nachod BE; Joseph RA; Metzloff AE; Mitchell MJ
ACS Nano; 2024 Jun; 18(25):16151-16165. PubMed ID: 38861479
[TBL] [Abstract][Full Text] [Related]
10. Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing.
El-Mayta R; Padilla MS; Billingsley MM; Han X; Mitchell MJ
J Vis Exp; 2023 Jan; (191):. PubMed ID: 36744791
[TBL] [Abstract][Full Text] [Related]
11. Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device.
Maeki M; Okada Y; Uno S; Niwa A; Ishida A; Tani H; Tokeshi M
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35404350
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Studies of an Automated Lipid Nanoparticle Reveal Critical Pharmaceutical Properties Associated with Enhanced mRNA Functional Delivery In Vitro and In Vivo.
Cui L; Hunter MR; Sonzini S; Pereira S; Romanelli SM; Liu K; Li W; Liang L; Yang B; Mahmoudi N; Desai AS
Small; 2022 Mar; 18(9):e2105832. PubMed ID: 34914866
[TBL] [Abstract][Full Text] [Related]
13. Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver.
Zhang R; El-Mayta R; Murdoch TJ; Warzecha CC; Billingsley MM; Shepherd SJ; Gong N; Wang L; Wilson JM; Lee D; Mitchell MJ
Biomater Sci; 2021 Feb; 9(4):1449-1463. PubMed ID: 33404020
[TBL] [Abstract][Full Text] [Related]
14. Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions.
Reinhart AG; Osterwald A; Ringler P; Leiser Y; Lauer ME; Martin RE; Ullmer C; Schumacher F; Korn C; Keller M
Mol Pharm; 2023 Dec; 20(12):6492-6503. PubMed ID: 37975733
[TBL] [Abstract][Full Text] [Related]
15. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs.
Suzuki Y; Ishihara H
Drug Metab Pharmacokinet; 2021 Dec; 41():100424. PubMed ID: 34757287
[TBL] [Abstract][Full Text] [Related]
16. Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening.
Guimaraes PPG; Zhang R; Spektor R; Tan M; Chung A; Billingsley MM; El-Mayta R; Riley RS; Wang L; Wilson JM; Mitchell MJ
J Control Release; 2019 Dec; 316():404-417. PubMed ID: 31678653
[TBL] [Abstract][Full Text] [Related]
17. Real-Time pH-Dependent Self-Assembly of Ionisable Lipids from COVID-19 Vaccines and In Situ Nucleic Acid Complexation.
Yu H; Angelova A; Angelov B; Dyett B; Matthews L; Zhang Y; El Mohamad M; Cai X; Valimehr S; Drummond CJ; Zhai J
Angew Chem Int Ed Engl; 2023 Aug; 62(35):e202304977. PubMed ID: 37391876
[TBL] [Abstract][Full Text] [Related]
18. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
Schoenmaker L; Witzigmann D; Kulkarni JA; Verbeke R; Kersten G; Jiskoot W; Crommelin DJA
Int J Pharm; 2021 May; 601():120586. PubMed ID: 33839230
[TBL] [Abstract][Full Text] [Related]
19. Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery.
Patel SK; Billingsley MM; Mukalel AJ; Thatte AS; Hamilton AG; Gong N; El-Mayta R; Safford HC; Merolle M; Mitchell MJ
Theranostics; 2024; 14(1):1-16. PubMed ID: 38164140
[TBL] [Abstract][Full Text] [Related]
20. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
